The pharmacology of Tourette syndrome

Journal of Neural Transmission

Volumn 120, Issue 4, 2013, Pages 689-694

  Thomas, Roji ^a   Cavanna, Andrea E ^a,b,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Guidelines; Medication; Pharmacotherapy; Tics; Tourette syndrome; Treatment

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; BENZAMIDE DERIVATIVE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CANNABINOID; CLONAZEPAM; CLONIDINE; CLOZAPINE; DESIPRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ETIRACETAM; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE; PIMOZIDE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; TETRABENAZINE; TETRAHYDROCANNABINOL; TIAPRIDE; TOPIRAMATE; TRIFLUOPERAZINE; ZIPRASIDONE;

AKATHISIA; ANXIETY; BRAIN DEPTH STIMULATION; CONFERENCE PAPER; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG WITHDRAWAL; EXCITEMENT; EXTRAPYRAMIDAL SYMPTOM; FACIAL TICS; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEART DISEASE; HUMAN; HYPERKINESIA; HYPERKINETIC MOVEMENT DISORDER; HYPERPROLACTINEMIA; INSOMNIA; IRRITABILITY; LOW DRUG DOSE; METABOLIC DISORDER; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; PARADOXICAL DISINHIBITION; PARKINSONISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SIDE EFFECT; SLEEP DISORDER; STUTTERING; TIC; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; HUMANS; TICS; TOURETTE SYNDROME;

EID: 84875705762     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-0979-z     Document Type: Conference Paper

References (39)

1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed., text revision. American Psychiatric Association: Washington, DC
2. Borison RL, Ang L, Hamilton WJ, Diamond BI, Davis JM (1983) Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull 11:205-208 (Pubitemid 13016843)
3. Cath DC, Hedderly T, Ludolph AG, Stern JS, Murphy T, Hartmann A, Czernecki V, Robertson MM, Martino D, Munchau A, Rizzo R, ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment. Eur Child Adolesc Psychiatry 20:155-171
4. Cavanna AE, Servo S, Monaco F, Robertson MM (2009) The behavioral spectrum of Gilles de la Tourette syndrome. J Neuropsychiatry Clin Neurosci 21:13-23
5. Cavanna AE, Selvini C, Termine C, Luoni C, Eddy CM, Rickards H (2012) Tolerability profile of aripiprazole in patients with Tourette syndrome. J Psychopharmacol 26:891-895
6. Dion Y, Annable L, Sandor P, Chouinard G (2002) Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 22:31-39 (Pubitemid 34101290)
7. Drtilkova I, Balastikova B, Lemanova H, Zak J (1994) Therapeutic effects of clonidine and clonazepam in children with tick syndrome. Homeostasis Health Dis 35:296
8. Eddy CM, Rickards HE, Cavanna AE (2011) Treatment strategies for tics in Tourette syndrome. Ther Adv Neurol Disord 4:25-45
9. Goetz CG (1992) Clonidine and clonazepam in Tourette syndrome. Adv Neurol 58:245-251
10. Gulisano M, Calì PV, Cavanna AE, Eddy C, Rickards H, Rizzo R (2011) Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 32:1213-1217
11. Hassan N, Cavanna AE (2012) The prognosis of Tourette syndrome: implications for clinical practice. Funct Neurol 27:23-27
12. Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J (2012) Update on the role of antipsychotics in the treatment of Tourette syndrome. Neuropsychiatr Dis Treat 8:95-104
13. Jankovic J, Beach J (1997) Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48:358-362 (Pubitemid 27087603)
14. Jankovic J, Jimenez-Shahed J, Brown L (2010) A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 81:70-73
15. Ji WD, Li Y, Li N, Guo BY (2005) Olanzapine for treatment of Tourette syndrome: a double-blind randomized controlled trial. Chinese J Clin Rehab 9:66-68 (Pubitemid 40839062)
16. Liu ZS, Chen YH, Zhong YQ, Zou LP, Wang H, Sun D, Wang DB, Liao JX (2011) A multicentre controlled study on aripiprazole treatment for children with Tourette syndrome in China. Zhonghua Er Ke Za Zhi 49:572-576
17. McConville BJ, Fogelson MH, Norman AB, Klykylo WM, Manderscheid PZ, Parker KW, Sanberg PR (1991) Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am J Psychiatry 148:793-794
18. Muller-Vahl KR, Schneider U, Kolbe H, Emrich HM (1999) Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156:495
19. Muller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM (2002) Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57-61 (Pubitemid 34293234)
20. Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM (2003a) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459-465 (Pubitemid 36547292)
21. Muller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U (2003b) Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384-388
22. Muller-Vahl KR, Cath DC, Cavanna AE, Dehning S, Porta M, Robertson MM, Visser-Vandewalle V, ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. Eur Child Adolesc Psychiatry 20:209-217
23. Piedad JCP, Rickards HE, Cavanna AE (2012) What patients with gilles de la tourette syndrome should be treated with deep brain stimulation and what is the best target? Neurosurgery 71:173-192
24. Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D (2008) Tourette's syndrome and the role of tetrabenazine: review and personal experience. Clin Drug Investig 28:443-459 (Pubitemid 351821482)
25. Pringsheim T, Marras C (2009) Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2:CD006996
26. Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P (2012) Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry 57:133-143
27. Robertson MM (2011) Gilles de la Tourette syndrome: the complexities of phenotype and treatment. Br J Hosp Med 72:100-107
28. Robertson MM, Schneider V, Lees AJ (1990) Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropsychopharmacol 13:229-235 (Pubitemid 20181214)
29. Robertson MM, Eapen V, Cavanna AE (2009) The international prevalence, epidemiology and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res 67:475-483
30. Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ, ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatr 20:173-196
31. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G (1997) Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatr 154:1057-1062 (Pubitemid 27328819)
32. Sandor P, Musisi S, Moldofsky H, Lang A (1990) Tourette syndrome: a follow-up study. J Clin Psychopharmacol 10:197-199 (Pubitemid 20203774)
33. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130-1135 (Pubitemid 36418773)
34. Scahill L, Erenberg G, Berlin CM, Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J, Tourette Syndrome Association Medical Advisory Board: Practice Committee (2006) Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 3:192-206 (Pubitemid 44061705)
35. Shapiro AK, Shapiro E, Eisenkraft GJ (1983) Treatment of Gilles de la Tourette syndrome with clonidine and neuroleptics. Arch Gen Psychiatr 40:1235-1240 (Pubitemid 13015020)
36. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandell J, Nordlie J, Phillips RA (1989) Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatr 46:722-730 (Pubitemid 19198099)
37. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB (1995) The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind, placebo controlled study with clonidine and desipramine. Pediatrics 95:74-81
38. Steeves T, McKinlay BD, Gorman D, Billinghurst L, Day L, Carroll A, Dion Y, Doja A, Luscombe S, Sandor P, Pringsheim T (2012) Canadian guidelines for the evidence-based treatment of tic disorders: behavioural therapy, deep brain stimulation, and transcranial magnetic stimulation. Can J Psychiatry 57:144-151
39. Verdellen C, van de Griendt J, Hartmann A, Murphy T, ESSTS Guidelines Group (2012) European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry 20:197-207